Genetic Testing in KRAS- and EGFR-Mutant Lung Cancers
Nicholas Rohs, MD, of Mount Sinai Hospital discusses the importance of genetic testing in lung cancers that harbor KRAS and EGFR mutations.
Nicholas Rohs, MD, of Mount Sinai Hospital discusses the importance of genetic testing in lung cancers that harbor KRAS and EGFR mutations.
Rohs says that genetic testing is especially critical for patients with the lung adenocarcinoma subtype, which is the most common type of lung cancer. Two-thirds of lung adenocarcinoma have actionable mutations for which there are targeted therapies that can treat the disease.
Knowing that there are targeted therpies available for many lung adenocarcinomas is even more of a reason to perform testing on patients.
KRAS and EFGR are 2 of the most common mutations found in the patients subtype. A lot more is known about EFGR and there are numerus treatment options that are safe to use. On the other hand, KRAS has proven to be more of a challenge. Previously, KRAS mutations were considered “untargetable.” However, according to Rohs, this assumption has been challenged by recent success in early clinical trials.
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
